Impact Partnership Wealth LLC Purchases 2,909 Shares of Johnson & Johnson $JNJ

Impact Partnership Wealth LLC increased its position in Johnson & Johnson (NYSE:JNJ) by 183.6% during the 4th quarter, HoldingsChannel.com reports. The fund owned 4,493 shares of the company’s stock after buying an additional 2,909 shares during the period. Impact Partnership Wealth LLC’s holdings in Johnson & Johnson were worth $930,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently bought and sold shares of the company. Norges Bank bought a new position in Johnson & Johnson in the 4th quarter worth $6,924,523,000. Madison Wealth Partners Inc raised its holdings in Johnson & Johnson by 32.7% in the 4th quarter. Madison Wealth Partners Inc now owns 3,192 shares of the company’s stock worth $661,000 after acquiring an additional 787 shares during the period. Hilltop Partners LLC raised its holdings in Johnson & Johnson by 3.3% in the 4th quarter. Hilltop Partners LLC now owns 19,196 shares of the company’s stock worth $3,973,000 after acquiring an additional 618 shares during the period. Eurizon SLJ Capital Ltd bought a new position in Johnson & Johnson in the 4th quarter worth $545,000. Finally, Coyle Financial Counsel LLC raised its holdings in Johnson & Johnson by 76.6% in the 4th quarter. Coyle Financial Counsel LLC now owns 2,494 shares of the company’s stock worth $516,000 after acquiring an additional 1,082 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $225.16 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77. The firm has a market capitalization of $542.01 billion, a price-to-earnings ratio of 26.03, a P/E/G ratio of 2.26 and a beta of 0.27. The company’s fifty day moving average is $233.02 and its two-hundred day moving average is $224.82. Johnson & Johnson has a 52-week low of $149.04 and a 52-week high of $251.71.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The company had revenue of $24.06 billion for the quarter, compared to analyst estimates of $23.60 billion. During the same period last year, the business posted $2.77 EPS. The business’s quarterly revenue was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Equities research analysts forecast that Johnson & Johnson will post 11.57 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th will be given a dividend of $1.34 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.30. The ex-dividend date is Tuesday, May 26th. This represents a $5.36 annualized dividend and a dividend yield of 2.4%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 61.97%.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson reported updated Phase 1/1b data showing RYBREVANT plus LAZCLUZE delivered prolonged clinical benefit in atypical EGFR-mutated non-small cell lung cancer, with median overall survival nearing 3.5 years. This strengthens the case for the company’s lung cancer pipeline. Article Title
• Positive Sentiment: New Phase 3 MajesTEC-9 data showed TECVAYLI improved progression-free and overall survival versus standard of care in relapsed multiple myeloma, reinforcing Johnson & Johnson’s momentum in blood-cancer treatments and expanding confidence in the drug’s earlier-line use. Article Title
• Positive Sentiment: The FDA approved a label expansion for TREMFYA in psoriatic arthritis, adding evidence that it can help stop structural joint damage. That makes TREMFYA more differentiated in a large immunology market and may support future sales growth. Article Title
• Neutral Sentiment: Several analyst and market commentary pieces noted that JNJ has outperformed the Dow and that Wall Street sentiment remains moderately optimistic, but these were mostly retrospective and did not add new fundamental catalysts. Article Title
• Neutral Sentiment: Johnson & Johnson also announced it will host its second-quarter earnings conference call on July 15, which is routine corporate communication rather than a price-moving event on its own. Article Title
• Negative Sentiment: Broader commentary highlighted that J&J still faces exposure from patent-loss pressure on older products, even though oncology growth and MedTech demand are helping offset it. This remains an overhang on the stock’s longer-term earnings mix. Article Title

Analyst Ratings Changes

Several brokerages recently commented on JNJ. HSBC lifted their target price on shares of Johnson & Johnson from $265.00 to $280.00 and gave the stock a “buy” rating in a report on Tuesday, March 17th. TD Cowen started coverage on shares of Johnson & Johnson in a research report on Wednesday, April 8th. They issued a “buy” rating and a $250.00 price target on the stock. Rothschild & Co Redburn raised their price target on shares of Johnson & Johnson from $180.00 to $210.00 and gave the stock a “neutral” rating in a research report on Thursday, February 19th. Royal Bank Of Canada restated an “outperform” rating and issued a $265.00 price target on shares of Johnson & Johnson in a research report on Wednesday, April 15th. Finally, The Goldman Sachs Group raised their price target on shares of Johnson & Johnson from $265.00 to $275.00 and gave the stock a “buy” rating in a research report on Wednesday, April 15th. Twenty research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus target price of $253.04.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.